INTRODUCTION
Isocitrate dehydrogenase 1 encodes for the IDH1 enzyme, which plays important roles in cellular metabolism, energy production and maintenance of normal redox status in cells. IDH1 is localized in the cell cytoplasm and peroxisomes where it catalyzes the conversion of isocitrate to α-ketoglutarate (α-KG) and simultaneously reduces NADP to NADPH [1] . α-Ketoglutarate serves as a key intermediate in the tricarboxylic acid cycle (TCA) in cells, and as substrate for several important dioxygenase enzymes. NADPH is a key cofactor in the cholesterol and lipid synthesis pathways and also contributes to cell defense against oxidative damage induced by reactive oxygen species (ROS) [2] . Recent genome-wide mutation analysis studies revealed that gliomas frequently harbor mutations in IDH1 and, to a lesser extent, the homologous IDH2 genes [3, 4] . IDH1 mutations are present in over 75% of WHO grade 2 and grade 3 gliomas and in secondary gliomas that develop from lower-grade tumors [2, 4, 5] . IDH mutations are generally associated with better prognosis when compared to glioma patients with wild-type IDH (WT-IDH) tumors of the same histological type [4, 6] . The median overall survival of patients with IDH-mutated glioblastoma and anaplastic astrocytoma is approximately 2-3 times longer than for patients whose tumors have WT-IDH1 [4] , strongly suggesting the prognostic significance of IDH1 and IDH2 mutations in glioma [7] .
Studies suggest that IDH mutations also play significant roles in tumorigenesis. IDH mutation is an early genetic event in the formation of gliomas, and contributes to tumor pathogenesis through multiple mechanisms that are mediated by the neomorphic activity of the mutated IDH1 enzyme [5, 8, 9] . IDH mutation results in a loss of normal catalytic activity -conversion of isocitrate to α-KG -for the IDH enzyme but also imparts a new gain-of-function that enables the mutant IDH to convert α-KG to 2-hydroxyglutarate (2-HG) in a stereospecific manner (D-2-HG) [10] . Consequently, tumors that are positive for IDH1 mutation have ~100-fold higher levels of D-2-HG compared to tumors with normal IDH1 (WT-IDH1). Excessive D-2-HG in IDH1-mutated cells competitively inhibits several key cellular dioxygenases that are normally dependent on α-KG as a co-factor for their enzyme activity [11] . This competitive inhibition is presumed to be due to the structural similarity of D-2-HG with the α-KG, and results in the impairment of the activity of multiple cellular dioxygenases leading to stabilization and activation of the transcription factor hypoxia-inducible factor-1α (HIF-1α), epigenetic dysregulation leading to histone methylation and DNA hypermethylation, and impairment of normal collagen maturation [12] [13] [14] . IDH1 mutations also directly impact the cellular metabolism of small biochemicals such as amino acids, glutathione derivatives and tricarboxylic acid (TCA) cycle intermediates, suggesting the occurrence of widespread metabolic changes in IDH1-mutated tumor cells [15, 16] .
In view of these diverse roles and the impact of IDH1 mutations on cellular metabolism and epigenetics, there is a strong rationale for development of noninvasive imaging methods (e.g. PET) to evaluate mutant IDH1 expression in gliomas. Such a method could enable determination of the IDH1 mutation status in glioma patients noninvasively, predict prognosis and assist in the design and implementation of novel therapeutics for patients with malignant brain tumors as well as other cancers that carry these mutations [2, 5] . In this work, we have synthesized and evaluated radiolabeled compounds that have inhibitory activity against the most commonly occurring IDH1 mutation subtype, IDH1-R132H [17] . Selected compounds were labeled with radioiodine and/or fluorine-18, and in vitro studies and preliminary in vivo studies were conducted using the labeled inhibitors in order to assess their suitability as probes for mutant IDH1.
RESULTS AND DISCUSSION

Chemistry
Butyl-phenyl sulfonamide inhibitors of mutant IDH were among the first compounds shown to inhibit mutant IDH1 activity in vitro. From this chemical class, N-(4-butylphenyl)-3-(4-(2-methoxyphenyl)piperazine-1-carbonyl)-4-methylbenzenesulfonamide A (Fig. 1) was chosen as the reference compound, which has an IC 50 value of <1 µM against the mutant IDH1-R132H enzyme [17] . A series of nonradioactive iodo-and/or fluorinated analogs of A were synthesized for structure-activity relationship studies and to identify potent inhibitors for radiolabeling (Fig.   2) . The basic synthesis route involved the reaction of commercially available 5-(N-(4-butylphenyl)sulfamoyl)-2-methylbenzoic acid with appropriate phenyl piperazine derivative in the presence of the coupling reagents EDC and HOBt in DMF (Scheme 1) [17] . For the iodophenyl analogs 1 and 2, the piperazine derivatives 1-(2-iodophenyl)piperazine and 1-(4-iodophenyl)piperazine were synthesized following a literature report [17] , and were subsequently coupled to the benzoic acid derivative in 62% yield for 1 and 71% yield for 2. The fluoroethyl analogs 4 and 5 were synthesized by introduction of a fluoroethoxy function at the ortho-or para-position of the phenyl ring in the phenyl piperazine moiety. For these reactions, fluoroethoxyphenyl piperazine derivatives were synthesized by using the corresponding phenol piperazine via a 3-step synthesis route [18] . First, the secondary amine function in the piperazine ring was protected with a Boc-group in quantitative yields. Fluoroethylation of the boc-protected 2-or 4-hydroxypheyl piperazine was achieved by using fluoroethyl bromide (FEtBr) in about 75% yield. Removal of the boc protective groups with a mixture of TFA and CH 2 Cl 2 (50/50, v/v) yielded the fluoroethoxyphenyl piperazine derivatives in quantitative yields.
The synthesized 2-and 4-fluoroethoxyphenyl piperazine analogs were then reacted with the methylbenzoic acid derivative to obtain the fluoroethoxy analogs 4 and 5 in 40-47% yield (Scheme 1). For compound 3, the iodine atom was introduced in place of the methyl group in the methylbenzoic acid derivative in a two-step synthesis (9) and was then coupled to 1-(-2-methoxyphenyl)piperazine in 59% yield (Scheme 2). Scheme 3 shows the synthesis route for the fluoroalkyl derivatives 6 and 7. Introduction of the fluorine atom into the side chain in these compounds was achieved by means of a fluorpropyl (6) or a fluorobutyl (7) function. For these syntheses, the fluoroalkyl aniline derivatives 12a and 12b were synthesized first, and were subsequently reacted with 5-(chlorosulfonyl)-2-methylbenzoic acid to obtain 13a or 13b. The synthesis of 4-(3-fluoropropyl)aniline 12a was achieved using commercially available 3-(4-nitrophenyl)propionic acid (structure not shown)
where the carboxylic acid function was first reduced to an alcohol using borane in THF to get 10a. Treatment of the alcohol derivatives 10a and 10b with XTalFluor-M in the presence of DBU as the promotor yielded the fluoroalkyl-nitrobenzene analogs 11a and 11b in 41% and 53% yield, respectively (Scheme 3). Reduction of the nitro group to an amino function by Pd/Ccatalized hydrogenation followed by sulfamoylation of the anilines with 5-(chlorosulfonyl)-2-methylbenzoic afforded the fluoroalkylphenyl sulfonamide intermediates 13a and 13b in 69-74% yield. Compounds 13a and 13b were then coupled to 1-(2-methoxyphenyl)piperazine to obtain the final compounds 6 and 7 in 85% and 78% yield, respectively. The synthesis of the radiolabeling precursors 14 and 15 was achieved as described for 1 using 1-(2-bromophenyl)piperazine and 2-(piperazin-1-yl)phenol as starting materials and with a chemical yield of 77% and 54%, respectively. The synthesized compounds were evaluated by mass spectrometry for identity confirmation and characterized by NMR spectroscopy. The purity of the synthesized nonradioactive analogs and the radiolabeling precursors was verified by analytical HPLC, and was found to be between 94% and 98%.
Inhibitory Activity of the Nonradioactive Analogs against the Mutant IDH1
The inhibitory activity of the nonradioactive iodo-and fluoro analogs was evaluated by incubating serially-diluted (2-fold) solutions of the compounds with purified IDH1-R132H enzyme in multiwell plates. Figure 2 shows the half-maximal inhibitory concentration (IC 50 ) values and the maximal enzyme inhibition achieved for the synthesized compounds in the inhibition assays. While the para-fluoroethoxy derivative 5 displayed partial inhibitory activity with an IC 50 of 1.2 µM but a maximum enzyme inhibition of only ~30%, the para-iodo analog 2 did not show any significant activity against mutant IDH1, suggesting that the structural modification at the paraposition was not well-tolerated for the binding affinity. Introduction of a fluorine atom in place of hydrogen or the terminal methyl group in the butyl side chain also resulted in good retention of inhibitory activity for compounds 6 and 7, with IC 50 values of 2.7 µM and 2.4 µM, and an inhibitory efficiency of 99% and 81%, respectively.
We next evaluated the ability of the nonradioactive compounds to bind to and inhibit mutant IDH1 activity in tumor cells that are positive for the IDH1-R132H mutation. For these experiments, an astrocytoma cell line with a native IDH1-R132H mutation was used [19] with an isogenic astrocytoma cell line with WT-IDH1 serving as a control. Cells were treated with the inhibitors 1 or 4 (50 µM), and the 2-HG concentrations in cell supernatants were analyzed by LC/MS at 4 and 8 h after incubation [14, 19] . Comparison of 2-HG levels in vehicle-treated cell lines showed that the concentration of 2-HG in IDH1-mutated astrocytoma cells was about 30-fold higher than that in isogenic wild-type IDH1 control cells (WT-IDH1), confirming the expression of mutant IDH1 protein and its neomorphic activity in the IDH1-mutated astrocytoma cell line (Fig. 4) . Addition of the nonradioactive inhibitor 1 or 4 to the culture media decreased 2-HG concentration in mutant IDH1 cell supernatants by 43% for compound 1 and by 50% for compound 4 at 8 h post-incubation. It is likely that the residual amounts of 2-HG that were present inside the cells prior to their incubation with the inhibitors are exported into the supernatant with time and partially contributed to the concentrations observed at 8 h after incubation with the test compounds. These results are consistent with recent studies that reported a 2-HG inhibitory half-life (50% inhibition) of about 5 h for a structurally unrelated mutant IDH inhibitor [20] , and also suggest that incubation times of up to 48 h may be required to achieve complete inhibition of 2-HG production by mutant IDH1 inhibitors in cell based assays [20, 21] . Nevertheless, these results confirm the ability of the unlabeled inhibitors 1 and 4 to inhibit the mutant IDH1 enzyme in tumor cells that are positive for an IDH1 mutation.
Radiochemistry
Radioiodination of 1 ([ 125 I]1) was achieved through a Cu(I)-catalyzed Br-to-*I exchange reaction in acidic and reducing conditions using gentisic acid as depicted in Scheme 4 [22] . After labeling, the crude reaction mixture was purified by RP-HPLC, and the HPLC peak 
Tissue Distribution Studies
Tissue distribution studies were conducted using [ 125 I]1 in order to evaluate the normal tissue distribution characteristics of the labeled compound and to assess its suitability for development as an imaging agent for mutant IDH1. Table 1 shows the % ID and 
Cell Uptake Studies
The uptake of the labeled inhibitors in mutant IDH expressing cells was evaluated using the [24, 25] characteristics, suggesting practical evaluation of all candidate radiotracers in relevant biological models (in vitro and in vivo) before a lead compound is identified for new imaging targets such as mutant IDH1. While high lipophilicity may increase the risk of non-specific binding of small molecule compounds to proteins, studies suggest that efficient cell membrane permeability requires a LogP of > 0.8 for compounds that are undergoing passive diffusion to enter cells [26] . Using the information obtained from the present study, work is in progress to synthesize and evaluate labeled compounds from additional chemical classes that have been shown to have higher potency than the butyl-phenyl sulfonamide inhibitors and also inhibited the neomorphic activity of mutant IDH1 in tumor models in vivo [21, 27] . Further optimization of these compounds by decreasing the lipophilicity and increasing the inhibitory potency may yield compounds with more favorable uptake characteristics for labeling mutant IDH1 expressing tumor cells with radionuclides suitable for PET imaging.
EXPERIMENTAL SECTION
Reagents and General Methods
The solvents and regents used in this work were purchased from VWR International, LLC, or from Sigma-Aldrich, and were used as supplied. The reference compound N-(4-butylphenyl)-3- Gold HPLC system equipped with gradient solvent system, variable wavelength UV detector set at 254 nm, and a radiometric detector. Data were acquired and analyzed using the software (32 The crude mixture was diluted with water (80 mL) and extracted with ethyl acetate (3 × 50 mL).
The combined organic layers were washed with water followed by brine, and filtered over sodium sulfite. The filtrate was concentrated under reduced pressure, and subjected to purification using silica gel eluted with gradient mixtures of ethyl acetate (EtOAc) and hexanes (0→50%) to obtain 1 as an off-white solid (0.087 g, 62% yield), mp: 83-84 °C. 
N-(4-Butylphenyl)-3-(4-(2-(2-fluoroethoxy)phenyl)piperazine-1-carbonyl)-4-
methylbenzenesulfonamide (4)
Compound 4 was prepared a described for 1, but using 1-(2-(2-fluoroethoxy)phenyl)piperazine 
5-(Chlorosulfonyl)-2-iodobenzoic acid (8)
Chlorosulfonic acid (50 mL, 752 mmol) was cooled in an ice-NaCl bath under an atmosphere of argon. To this was added o-iodobenzoic acid (12.4 g, 50 mmol) in small portions over 5 min.
The cooling bath was removed and the solution was allowed to warm to room temperature then heated overnight to 115°C (oil bath temperature). T he reaction mixture was then cooled to RT and poured slowly over ice (~1L). The resulting precipitate was filtered, washed with water (2 × 200 mL) and dried. The solid residue was dissolved in EtOAc (400 mL) and the resulting amber solution was washed with brine (3 x 400 mL) then dried (Na 2 SO 4 ). The drying agent was removed by filtration and the filtrate was concentrated to dryness under reduced pressure to afford the crude product (11 g, 63%) as a light orange solid. The crude product was used in the next step without further purification.
5-(N-(4-Butylphenyl)sulfamoyl)-2-iodobenzoic acid (9)
Solid 5-(chloromethylsulfonyl)-2-iodobenzenecarboxylic acid 8 (5.0 g, 11 mmol, 1.1 eq.) was added in one portion to a solution of 4-butylaniline (1.6 mL, 10 mmol) in pyridine (40 mL). The reaction was allowed to warm to RT as the cooling bath melted. and the material was used without further characterization.
N-(4-Butylphenyl)-4-iodo-3-(4-(2-methoxyphenyl)piperazine-1-
carbonyl)benzenesulfonamide (3)
N,N-Diisopropylethylamine (1.1 mL, 6.3 mmol, 4 eq.) was added in one portion at room temperature to a (near) solution of the acid 9 (0.713 g, 1.6 mmol), HOBt (0.37 g, 2.3 mmol, 1.5 eq.), EDC (0.45 g, 2.3 mmol, 1.5 eq.) and 1-(-2-methoxyphenyl)piperazine (0.9 g, 3.9 mmol, 2.5 eq.) in anhydrous CH 2 Cl 2 (25 mL 
1-(3-Fluoropropyl)-4-nitrobenzene (11a)
A solution of 3-(4-nitrophenyl)propan-1-ol 10 (2.5 g, 13. 
N-(4-(4-Fluorobutyl)phenyl)-3-(4-(2-methoxyphenyl)piperazine-1-carbonyl)-4-
methylbenzenesulfonamide (7)
N,N-Diisopropylethylamine (1.8 mL, 10.5 mmol, 4 eq.) was added in one portion at RT to a 
3-(4-(2-Bromophenyl)piperazine-1-carbonyl)-N-(4-butylphenyl)-4-methylbenzenesulfonamide (14)
This was synthesized as described for compound 1 using 1-(2-bromophenyl)piperazine (0. 
N-(4-Butylphenyl)-3-(4-(2-hydroxyphenyl)piperazine-1-carbonyl)-4-
methylbenzenesulfonamide (15)
This was synthesized as described for compound 1, but starting from 2-(piperazin-1-yl)phenol 
Mutant IDH1 Inhibition Assays
The inhibitory efficiency of the synthesized nonradioactive analogs against mutant IDH1 was evaluated using purified IDH1-R132H enzyme in standard 384-well plates. Recombinant IDH1-R132H protein was derived as described previously [10] by expression with a C-terminal 6×His
Tag in E. coli followed by purification using a Ni-NTA spin column (Qiagen, Hilden, Germany).
For inhibition assays, serially-diluted solutions of nonradioactive test compounds in DMSO (1 µL) were added to wells that were pre-loaded with 25 µL of substrate mixture consisting of α-ketoglutarate (2 mM) and NADPH (8 µM). After centrifugation of the plate at 300g for 3 min, a diluted solution of IDH1-R132H enzyme (25 µL; 7.5 ng/µL) was added to the reaction mixture.
After a second centrifugation, the mixture was incubated at RT for 50 min followed by the addition of developer mixture (25 µL) containing resazurin (30 µM) and diaphorase enzyme (36 µg/mL). The mixture was incubated for 5 min, and the fluorescence intensity in reaction mixtures was measured by reading the plates on a POLARstar Optima plate reader (BMG Labtech, Germany) using 544 nm and 590 nm as excitation and emission wavelengths, respectively. It should be noted that the fluorescence reaction is enabled by the conversion of resazurin to a highly fluorescent resorufin by the diaphorase enzyme, and the signal intensity is proportional to the unconsumed NADPH present in the reaction mixture. Efficient inhibition of the mutant IDH1
by the test compounds results in a high fluorescence signal due to the presence of high NADPH in the reaction mixture, whereas low fluorescence in wells is an indicative of uninhibited reactions.
Functional Inhibition Assay
The ability of compounds 1 and 4 to inhibit the neomorphic activity of the mutant, IDH1-R132H, was evaluated using isogenic anaplastic astrocytoma cell lines carrying a native IDH1-R132H mutation or WT-IDH1. The IDH1-R132H-mutated astrocytoma cell line was a subclone derived from a WHO grade III anaplastic astrocytoma; this line was described previously [19] . 
Tissue Distribution Studies
Tissue distribution studies were conducted for [ 
